Related Experiment Video
Updated: Mar 19, 2026

Comparative Analysis of Human Growth Hormone in Serum Using SPRi, Nano-SPRi and ELISA Assays
Published on: January 7, 2016
[Effects of growth hormone treatment on anthropometrics, metabolic risk, and body composition variables in small for
Esther Aurensanz Clemente1, Pilar Samper Villagrasa2, Ariadna Ayerza Casas3
1Departamento de Pediatría, Hospital de Barbastro, Barbastro, Huesca, España.
Insights
Recombinant human growth hormone (rhGH) treatment improves height and weight in small for gestational age (SGA) children. While it enhances body composition, close monitoring for potential insulin resistance is crucial.
Area of Science:
- Pediatrics
- Endocrinology
- Metabolic Disorders
Background:
- Small for gestational age (SGA) children without catch-up growth may benefit from recombinant human growth hormone (rhGH) therapy.
- These children are at an increased risk for developing metabolic syndrome, necessitating careful monitoring during treatment.
Purpose of the Study:
- To evaluate the effects of rhGH treatment on anthropometric, metabolic, and body composition variables in SGA children.
- To assess the potential risks and benefits of rhGH therapy in this specific patient population.
Main Methods:
- A cohort of 28 SGA children (mean age 8.79 years) received rhGH treatment over 4 years.
- Annual evaluations included anthropometric measurements, metabolic risk markers, and body composition analysis.
Main Results:
- rhGH significantly improved height, weight, and growth rate without altering BMI.
- Insulinaemia and HOMA index increased, indicating a trend towards insulin resistance.
- Body composition showed significant increases in lean mass and reductions in fat mass.
Conclusions:
- rhGH is effective in improving anthropometric parameters and body composition in SGA children.
- The observed increase in insulin resistance markers warrants close follow-up to determine long-term implications.
- Further studies are needed to ascertain if these changes persist into adulthood.
Introduction And Objectives:
Small for gestational age (SGA) children without catch-up growth can benefit from treatment with growth hormone (rhGH). However, they should be monitored very closely because they are at increased risk of metabolic syndrome.
Material And Method:
A group of 28 SGA children with a mean age of 8.79 years and undergoing treatment with rhGH were selected for evaluation. Over the course of 4 years, an annual evaluation was performed on the anthropometric variables (weight, height, body mass index [BMI], growth rate, blood pressure and waist perimeter), metabolic risk variables (glycaemia, glycosylated haemoglobin, cholesterol ratio, insulinaemia, insulin-like growth factor 1[IGF1], IGF binding protein-3 [IGFBP-3], IGF1/IGFBP3 ratio, and HOMA index), and body composition variables.
Results:
Treatment with rhGH was associated with a significant increase in height (-2.76±.11 SD to -1.53±.17 SD, P=.000), weight (-1.50±.09 SD to -1.21±.13 SD; P=.016), and growth rate (-1.43±.35 SD to .41±.41 SD; P=.009), without a corresponding change in the BMI. Insulinaemia (9.33±1.93mU/ml to 16.55±1.72mU/ml; P=.044) and the HOMA index (3.63±.76 to 6.43±.67; P=.042) increased, approaching insulin resistance levels. No changes were observed in the lipid profile. Body composition changes were observed, with a significant increase in lean mass (73.19±1.26 to 78.74±1.31; P=.037), and a reduction of fat mass (26.81±1.26 to 21.26±1.31; P=.021).
Conclusion:
Treatment with rhGH is effective for improving anthropometric variables in SGA patients who have not experienced a catch-up growth. It also produces changes in body composition, which may lead to a reduction in risk of metabolic syndrome. However, some insulin resistance was observed. It is important to follow up this patient group in order to find out whether these changes persist into adulthood.
Related Concept Videos
Nature and Nurture
Hypoglycemia and Glucagon
Signs of Puberty
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Diabetes Mellitus: Type 2 and Gestational
Pathophysiology of Diabetes
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...

